All In Biotech

NDA 214581 · Novitium Pharma

Sovuna

Hydroxychloroquine Sulfate · Oral

Last checked: Nov 20, 2026Latest source record: Oct 10, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Jan 14, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

544

162 Phase 3, 62 recruiting

FAERS reports

40,482

35,382 serious, 4,537 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 8, 2024.

SOVUNA is an antimalarial and antirheumatic indicated for the: Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax in adult and pediatric patients. (1.1) Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported in adult and pediatric patients. (1.1) Treatment of rheumatoid arthritis in adults. (1.2) Treatment of systemic lupus erythematosus in adults. (1.3) Treatment of chronic discoid lupus erythematosus in adults. (1.4) Limitations of Use (1.1): SOVUNA is not recommended for the: Treatment of complicated malaria. Treatment of chloroquine or hydroxychloroquine-resistant strains of Plasmodium species. Treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. Prophylaxis of malaria in geographic areas where chloroquine resistance occurs. Prevention of relapses of P. vivax or P. ovale because it is not active against the hypnozoite liver stage forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline drug is necessary. 1.1 Malaria SOVUNA is indicated in adult and pediatric patients for the: Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax, and Plasmodium ovale. Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use: SOVUNA is not recommended for: Treatment of complicated malaria. Treatment of malaria by chloroquine or hydroxychloroquine-resistant strains of Plasmodium species [see Microbiology (12.4)]. Treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium...

Mechanism: Malaria Hydroxychloroquine is a 4-aminoquinoline antimalarial [see Microbiology (12.4)] and antirheumatic agent. Rheumatoid Arthritis, Systemic Lupus Erythematosus and Chronic Discoid Lupus Erythematosus The mechanisms underlying the anti-inflammatory and immunomodulatory effects of SOVUNA in the treatment of rheumatoid arthritis, chronic discoid lupus erythematosus and systemic lupus erythematosus are not fully known.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 14, 2022 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
2 products under this application
  • SOVUNA · HYDROXYCHLOROQUINE SULFATE 200MG · TABLET, ORAL · Prescription
  • SOVUNA · HYDROXYCHLOROQUINE SULFATE 300MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Hydroxychloroquine" as an intervention, any sponsor and status, largest first.

All 544 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective18,316
  • rheumatoid arthritis13,898
  • pain10,999
  • fatigue9,608
  • drug intolerance9,402
  • off label use8,673
  • arthralgia8,566
  • joint swelling8,555
  • contraindicated product administered8,205
  • alopecia7,852
  • abdominal discomfort7,845
  • rash7,825

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004173
2005231
2006174
2007243
2008402
2009368
2010660
2011421
2012723
2013208
2014143
2015370
2016904
20171,044
20181,597
20193,281
20207,825
20215,384
20224,541
20232,948
20243,572
20253,390
20261,880

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sovuna (Hydroxychloroquine Sulfate)

2024 spending

$25K

Beneficiaries

19

30 claims

Per beneficiary

$1,305

$16.02 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$24,802

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 895 on PubMed

Sponsor: Novitium Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.